Weight loss of 15% or greater was achieved by 66.7% of participants at 9 mg and 75.0% at 10 mg, indicating robust responses across most participants rather than outlier-driven averages
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, whereas semaglutide activates only the GLP-1 receptor and tirzepatide targets both GIP and GLP-1 receptors
Solution: be patient through the titration period
Once those are detoxed, your skin is healthier and looks refreshed
Managing your dosage timing and staying hydrated are essential to avoiding severe nausea or diarrhea
But you may have undiagnosed conditions elevated blood sugar, impaired kidney function, thyroid pathology that would change your management or represent a contraindication